1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Dengue - Pipeline Review, H1 2015

Dengue - Pipeline Review, H1 2015

  • January 2015
  • -
  • Global Markets Direct
  • -
  • 187 pages

Dengue - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Dengue - Pipeline Review, H1 2015’, provides an overview of the Dengue’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Dengue, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dengue and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Dengue
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Dengue and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Dengue products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Dengue pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Dengue
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Dengue pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Dengue - Pipeline Review, H1 2015
Table of Contents
Table of Contents 2
Introduction 8
Global Markets Direct Report Coverage 8
Dengue Overview 9
Therapeutics Development 10
Pipeline Products for Dengue - Overview 10
Pipeline Products for Dengue - Comparative Analysis 11
Dengue - Therapeutics under Development by Companies 12
Dengue - Therapeutics under Investigation by Universities/Institutes 16
Dengue - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Unknown Stage Products 21
Dengue - Products under Development by Companies 22
Dengue - Products under Investigation by Universities/Institutes 26
Dengue - Companies Involved in Therapeutics Development 28
Agilvax, Inc. 28
AltraVax Inc. 29
Arbovax, Inc. 30
BioDiem Ltd 31
Biotron Limited 32
Cocrystal Pharma, Inc. 33
Codagenix, Inc. 34
FIT Biotech Oyj 35
GlaxoSmithKline plc 36
Humabs BioMed SA 37
Immunovaccine, Inc. 38
Johnson and Johnson 39
Kineta, Inc. 40
MacroGenics, Inc. 41
Medivir AB 42
Merck and Co., Inc. 43
Molplex Ltd. 44
Myelo Therapeutics GmbH 45
NanoViricides, Inc. 46
Panacea Biotec Limited 47
PaxVax 48
Prosetta Antiviral Inc. 49
RFS Pharma, LLC 50
Sanofi Pasteur SA 51
Sarepta Therapeutics, Inc. 52
SIGA Technologies, Inc. 53
SKAU Vaccines ApS 54
Takeda Pharmaceutical Company Limited 55
TechnoVax, Inc. 56
Themis Bioscience GmbH 57
United Therapeutics Corporation 58
VaxInnate Corporation 59
Visterra, Inc. 60
Dengue - Therapeutics Assessment 61
Assessment by Monotherapy Products 61
Assessment by Target 62
Assessment by Mechanism of Action 64
Assessment by Route of Administration 66
Assessment by Molecule Type 68
Drug Profiles 70
BG-323 - Drug Profile 70
celgosivir hydrochloride - Drug Profile 71
dengue (tetravalent) vaccine - Drug Profile 72
dengue (tetravalent) vaccine - Drug Profile 73
dengue (tetravalent) vaccine 4 - Drug Profile 74
dengue [DENV-2] vaccine - Drug Profile 75
dengue [rDEN1delta30, rDEN2/4delta30(ME), rDEN3delta30/31 and rDEN4delta30] (tetravalent) vaccine - Drug Profile 76
dengue [serotypes 1,2,3,4] (tetravalent) vaccine - Drug Profile 77
dengue fever vaccine - Drug Profile 80
dengue vaccine - Drug Profile 81
dengue vaccine - Drug Profile 82
dengue vaccine - Drug Profile 83
dengue vaccine - Drug Profile 85
dengue vaccine - Drug Profile 86
dengue vaccine - Drug Profile 87
dengue vaccine - Drug Profile 88
dengue vaccine - Drug Profile 89
dengue vaccine (DENV-2) - Drug Profile 90
dengue vaccine (tetravalent) - Drug Profile 91
dengue vaccine (tetravalent) - Drug Profile 93
dengue vaccine (tetravalent) - Drug Profile 94
dengue vaccine [DEN-1 and DEN-2] - Drug Profile 95
dengue vaccine [DEN-2] - Drug Profile 96
dengue vaccine 3 - Drug Profile 97
dengue vaccine 4 - Drug Profile 99
dengue vaccines - Drug Profile 100
dengue virus vaccine - Drug Profile 101
dengue virus vaccine (tetravalent) - Drug Profile 102
DengueCide - Drug Profile 103
DENV-1 PIV - Drug Profile 104
DiTU - Drug Profile 105
DV-2-DeltaGVII - Drug Profile 106
DV-2-DeltaLIG - Drug Profile 107
DV-2-G460P - Drug Profile 108
ETX-101 - Drug Profile 110
GBV-001 - Drug Profile 111
GBV-006 - Drug Profile 112
GBV-012 - Drug Profile 113
GREDEN/V1-4 - Drug Profile 114
LCTA-949 - Drug Profile 115
LVM-142 - Drug Profile 116
modipafant - Drug Profile 117
Monoclonal Antibodies for Infectious Disease - Drug Profile 118
Monoclonal Antibodies to Inhibit prM and E Proteins for Dengue - Drug Profile 119
Monoclonal Antibody for Dengue - Drug Profile 120
Monoclonal Antibody for Dengue - Drug Profile 121
Myelo-001 - Drug Profile 122
PAV-866 - Drug Profile 123
Recombinant Peptide to Inhibit Dengue Protease for Dengue - Drug Profile 124
RNAi Oligonucleotide for Dengue - Drug Profile 125
rOAS - Drug Profile 126
RS-1137 - Drug Profile 127
RS-1142 - Drug Profile 128
RS-1145 - Drug Profile 129
RS-930 - Drug Profile 130
RS-961 - Drug Profile 131
Small Molecule for Dengue - Drug Profile 132
Small Molecule for Dengue - Drug Profile 133
Small Molecule Inhibitors of NS3 Protease for Dengue and West Nile Virus Infections - Drug Profile 134
Small Molecule to Inhibit NS3 Protease for Dengue - Drug Profile 135
Small Molecules for Dengue - Drug Profile 136
Small Molecules for Dengue - Drug Profile 137
Small Molecules Inhibiting M Protein for Dengue - Drug Profile 138
Small Molecules to Activate AMPK for Dengue - Drug Profile 139
Small Molecules to Inhibit Alpha-Glucosidase I and II for Viral Infections - Drug Profile 140
Small Molecules to Inhibit Furin for Dengue - Drug Profile 142
Small Molecules to Inhibit NS3 Protease for Dengue and West Nile Virus Infections - Drug Profile 143
Small Molecules to Inhibit NS4b for Dengue - Drug Profile 144
Small Molecules to Inhibit Protease for Dengue - Drug Profile 145
Small Molecules to Inhibit RNA Dependent RNA Polymerase for Dengue Virus Infections - Drug Profile 146
Small Molecules to Inhibit Serine Protease for Viral Infections - Drug Profile 147
ST-148 - Drug Profile 148
ST-324 - Drug Profile 149
ST-610 - Drug Profile 150
Synthetic Peptides for West Nile Virus and Dengue Virus Infections - Drug Profile 151
TAK-003 - Drug Profile 152
TVX-005 - Drug Profile 154
UV-4B - Drug Profile 155
V-180 - Drug Profile 156
Viral PMO-X - Drug Profile 157
VIS-513 - Drug Profile 158
Dengue - Recent Pipeline Updates 159
Dengue - Dormant Projects 165
Dengue - Discontinued Products 167
Dengue - Product Development Milestones 168
Featured News and Press Releases 168
Appendix 180
Methodology 180
Coverage 180
Secondary Research 180
Primary Research 180
Expert Panel Validation 180
Contact Us 181
Disclaimer 181

List of Tables

Number of Products under Development for Dengue, H1 2015 16
Number of Products under Development for Dengue - Comparative Analysis, H1 2015 17
Number of Products under Development by Companies, H1 2015 19
Number of Products under Development by Companies, H1 2015 (Contd..1) 20
Number of Products under Development by Companies, H1 2015 (Contd..2) 21
Number of Products under Investigation by Universities/Institutes, H1 2015 23
Comparative Analysis by Late Stage Development, H1 2015 24
Comparative Analysis by Clinical Stage Development, H1 2015 25
Comparative Analysis by Early Stage Development, H1 2015 26
Comparative Analysis by Unknown Stage Development, H1 2015 27
Products under Development by Companies, H1 2015 28
Products under Development by Companies, H1 2015 (Contd..1) 29
Products under Development by Companies, H1 2015 (Contd..2) 30
Products under Development by Companies, H1 2015 (Contd..3) 31
Products under Investigation by Universities/Institutes, H1 2015 32
Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 33
Dengue - Pipeline by Agilvax, Inc., H1 2015 34
Dengue - Pipeline by AltraVax Inc., H1 2015 35
Dengue - Pipeline by Arbovax, Inc., H1 2015 36
Dengue - Pipeline by BioDiem Ltd, H1 2015 37
Dengue - Pipeline by Biotron Limited, H1 2015 38
Dengue - Pipeline by Cocrystal Pharma, Inc., H1 2015 39
Dengue - Pipeline by Codagenix, Inc., H1 2015 40
Dengue - Pipeline by FIT Biotech Oyj, H1 2015 41
Dengue - Pipeline by GlaxoSmithKline plc, H1 2015 42
Dengue - Pipeline by Humabs BioMed SA, H1 2015 43
Dengue - Pipeline by Immunovaccine, Inc., H1 2015 44
Dengue - Pipeline by Johnson and Johnson, H1 2015 45
Dengue - Pipeline by Kineta, Inc., H1 2015 46
Dengue - Pipeline by MacroGenics, Inc., H1 2015 47
Dengue - Pipeline by Medivir AB, H1 2015 48
Dengue - Pipeline by Merck and Co., Inc., H1 2015 49
Dengue - Pipeline by Molplex Ltd., H1 2015 50
Dengue - Pipeline by Myelo Therapeutics GmbH, H1 2015 51
Dengue - Pipeline by NanoViricides, Inc., H1 2015 52
Dengue - Pipeline by Panacea Biotec Limited, H1 2015 53
Dengue - Pipeline by PaxVax, H1 2015 54
Dengue - Pipeline by Prosetta Antiviral Inc., H1 2015 55
Dengue - Pipeline by RFS Pharma, LLC, H1 2015 56
Dengue - Pipeline by Sanofi Pasteur SA, H1 2015 57
Dengue - Pipeline by Sarepta Therapeutics, Inc., H1 2015 58
Dengue - Pipeline by SIGA Technologies, Inc., H1 2015 59
Dengue - Pipeline by SKAU Vaccines ApS, H1 2015 60
Dengue - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 61
Dengue - Pipeline by TechnoVax, Inc., H1 2015 62
Dengue - Pipeline by Themis Bioscience GmbH, H1 2015 63
Dengue - Pipeline by United Therapeutics Corporation, H1 2015 64
Dengue - Pipeline by VaxInnate Corporation, H1 2015 65
Dengue - Pipeline by Visterra, Inc., H1 2015 66
Assessment by Monotherapy Products, H1 2015 67
Number of Products by Stage and Target, H1 2015 69
Number of Products by Stage and Mechanism of Action, H1 2015 71
Number of Products by Stage and Route of Administration, H1 2015 73
Number of Products by Stage and Molecule Type, H1 2015 75
Dengue Therapeutics - Recent Pipeline Updates, H1 2015 165
Dengue - Dormant Projects, H1 2015 171
Dengue - Discontinued Products, H1 2015 173

List of Figures

Number of Products under Development for Dengue, H1 2015 16
Number of Products under Development for Dengue - Comparative Analysis, H1 2015 17
Number of Products under Development by Companies, H1 2015 18
Number of Products under Investigation by Universities/Institutes, H1 2015 22
Comparative Analysis by Clinical Stage Development, H1 2015 25
Comparative Analysis by Early Stage Products, H1 2015 26
Assessment by Monotherapy Products, H1 2015 67
Number of Products by Stage and Top 10 Targets, H1 2015 68
Number of Products by Top 10 Mechanism of Actions, H1 2015 70
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 71
Number of Products by Top 10 Routes of Administration, H1 2015 72
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 73
Number of Products by Top 10 Molecule Types, H1 2015 74
Number of Products by Stage and Top 10 Molecule Types, H1 2015 75

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

  • $ 10995
  • Industry report
  • October 2016
  • by Global Data

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. It is characterized ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

  • $ 6995
  • Industry report
  • December 2016
  • by GBI Research

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations Summary Hepatitis C is a blood-borne viral infection ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.